A Clinical Study of Legend Biotech BCMA-chimeric Antigen Receptor Technology in Treating Relapsed/Refractory (R/R) Multiple Myeloma Patients
Phase of Trial: Phase I/II
Latest Information Update: 29 Jan 2018
At a glance
- Drugs LCAR-B38M CAR-T cell therapy (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Proof of concept
- Acronyms LEGEND-2
- Sponsors Nanjing Legend Biotech
- 23 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 31 Dec 2018.
- 05 Jul 2017 Status changed from active, no longer recruiting to recruiting.
- 25 Jun 2017 Results (n=22; data cut off: 20 Feb,2017) presented at the 22nd Congress of the European Haematology Association.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History